BioCatalystWatch
PALIWorkspace / PALI / OverviewCompany library
Price
Market cap
Next catalystExpected Q1 2027PALI-2108 — planned ASCENTRA-CD · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

PALI-2108

PDE4 × PDE4B

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

PALI-2108

PDE4 × PDE4B

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

Partner / License out

PreINDP1P2P3FilingApproved

Cell therapy

PreINDP1P2P3FilingApproved

History / paused

PALI-2108

PDE4 × PDE4B

PreINDP1P2P3FilingApproved
PALI-2108

PDE4 × PDE4B

PreINDP1P2P3FilingApproved

Serine proteases

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

PALI PR & News

PR & News

PALI SEC archive